Post by cathode on Jan 21, 2016 20:30:40 GMT -5
If you search for:
"Applied Receptor Sciences, Mill Creek, WA 98012, USA"
Some interesting abstracts about receptors and drug administration. Maybe life sciences is a subsidiary? Again, not sure if this is any relation but is the closest I could find.
My searches continued to yield one and only one name -- Jeffrey M Herz. In 1997 he was publishing with the affiliation of "Applied Receptor Sciences", but looking at his history of patents, he has worked hand in hand with Omeros Corp -- based in Seattle and a NASDAQ public company. This relation between Mr. Herz and Omeros goes from the mid nineties to current. Mr. Herz is currently the president and CEO of Algomedix Inc, founded in 2010 and based in Mill Creek, WA. He has a history of working on receptor-molecule interactions. These seem to be regarding the inhibition of pain, inflammation, and spasms amongst others.
Some links -- hyperlinks aren't working
www.linkedin.com/in/jeffrey-herz-b5b97b7
www.linkedin.com/in/william-j-thomsen-86009012 <--- Algomedix Director of PharmaFrom the "highlights" of Dr. Thomsen, emphasis added by me:
Highlights include:
-Drug discovery and development expertise in multiple therapeutic areas including:
CNS diseases (depression,schizophrenia, anxiety, sleep, arousal, migraine)
Metabolic/endocrine diseases (obesity, type II diabetes, hyperthyroidism, osteoporosis)
Cardiovascular diseases (hypertension, CAD, CHF, PAH)
Immune diseases (inflammation and autoimmune)
Pain (inflammatory and neuropathic)
Renal diseases
Cancer
-Drug discovery and development expertise in multiple therapeutic areas including:
CNS diseases (depression,schizophrenia, anxiety, sleep, arousal, migraine)
Metabolic/endocrine diseases (obesity, type II diabetes, hyperthyroidism, osteoporosis)
Cardiovascular diseases (hypertension, CAD, CHF, PAH)
Immune diseases (inflammation and autoimmune)
Pain (inflammatory and neuropathic)
Renal diseases
Cancer
More on Omeros Corporation:
Their PPS doubled in Aug 2015 when they announced positive results from trials related to the treatment of thrombotic microangiopathies, which are clots of platelets that occur in small blood vessels. This can cause low platelet counts and the rupturing of red blood cells. Their drug works by inhibiting a key pro-inflammatory protein that is part of the immune system. Press Release 2015-08-18
Interesting bits from the press release:
A rare and devastating family of disorders, TMAs are characterized by thrombi or clumps of aggregated platelets in small blood vessels, which lead to thrombocytopenia (below-normal platelet counts) and schistocytes (fragmentation in red blood cells) that can cause dangerously low oxygen levels in organs like the brain and kidney as well as anemia. Thrombotic microangiopathies are life-threatening and can occur both in children and adults. While thrombi, thrombocytopenia and schistocytes are hallmarks of TMAs, other markers of damage within the blood vessels include an elevated plasma lactate dehydrogenase (LDH) and undetectable or reduced plasma haptoglobin levels. In addition, an elevated creatinine level – a result of the kidney damage caused by thrombi – is an indicator of impaired kidney function in patients who are not on renal dialysis.
There have been no confirmed clinically meaningful drug-related adverse events in any clinical trials with OMS721. [...] The FDA has cleared OMS721 for chronic dosing in clinical trials.
"We are excited by the data from this Phase 2 clinical trial with OMS721, both with respect to aHUS and TTP patients," stated Gregory A. Demopulos M.D., chairman and chief executive officer of Omeros. "Based on clinical data, we expect that we can deliver OMS721 either subcutaneously or intravenously at a frequency and dose that are both convenient and comfortable for patients while effectively eliminating lectin-pathway activity. Compassionate use in aHUS patients has begun, and we look forward to advancing to the fixed-dose stage of the trial and discussing Phase 3 trial design with the FDA later this year."
Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. [...] Omeros has received both Orphan Drug status and Fast Track designation from the U.S. FDA for its lead human MASP-2 antibody OMS721. An ongoing Phase 2 clinical program is evaluating OMS721 in the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and stem cell transplant-related TMAs. An investigator-requested compassionate use program for OMS721 is also underway. Chronic toxicity studies with systemically delivered OMS721 demonstrated no drug-related adverse events and, in addition to potential intravenous administration, Omeros plans to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. [...] Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntington's disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures.
There have been no confirmed clinically meaningful drug-related adverse events in any clinical trials with OMS721. [...] The FDA has cleared OMS721 for chronic dosing in clinical trials.
"We are excited by the data from this Phase 2 clinical trial with OMS721, both with respect to aHUS and TTP patients," stated Gregory A. Demopulos M.D., chairman and chief executive officer of Omeros. "Based on clinical data, we expect that we can deliver OMS721 either subcutaneously or intravenously at a frequency and dose that are both convenient and comfortable for patients while effectively eliminating lectin-pathway activity. Compassionate use in aHUS patients has begun, and we look forward to advancing to the fixed-dose stage of the trial and discussing Phase 3 trial design with the FDA later this year."
Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage or microbial infection. [...] Omeros has received both Orphan Drug status and Fast Track designation from the U.S. FDA for its lead human MASP-2 antibody OMS721. An ongoing Phase 2 clinical program is evaluating OMS721 in the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and stem cell transplant-related TMAs. An investigator-requested compassionate use program for OMS721 is also underway. Chronic toxicity studies with systemically delivered OMS721 demonstrated no drug-related adverse events and, in addition to potential intravenous administration, Omeros plans to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. [...] Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntington's disease, schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures.
Dr. Herz has patents with Dr. Demopulos and Omeros Corp primarily related to opthalmologic and urologic applications.
